Pharma Technical Development US Biologics, Genentech, South San Francisco, California, USA.
Biologics Process Research & Development, Merck & Co., Inc., Kenilworth, New Jersey, USA.
Biotechnol Prog. 2022 Jan;38(1):e3207. doi: 10.1002/btpr.3207. Epub 2021 Sep 24.
The year 2020 brought the onslaught of a global crisis in the form of the COVID-19 pandemic. While nearly every facet of everyday life and work was impacted by the pandemic, the biopharmaceutical industry found silver linings in innovation, partnership, and resiliency, all of which contributed to unprecedented speed in developing and delivering vaccines and therapies. The 7th International Conference on Accelerating Biopharmaceutical Development (AccBio 2021) brought together industry leaders to share experiences from the past year and discuss how lessons learned from the pandemic can be carried forward into the future of biopharmaceutical development. Presenters highlighted examples such as introducing biotherapeutics derived from non-clonal cell pools into the clinic, developing modular or platform technologies, and taking novel risks, among others. These strategies for enabling speed to clinic and launch, as well as for sustaining a robust supply chain, are likely to be integrated into future programs to ensure biomanufacturing resiliency and get medicines to patients faster than pre-pandemic times.
2020 年，COVID-19 大流行以全球性危机的形式袭来。虽然大流行几乎影响了日常生活和工作的方方面面，但生物制药行业在创新、合作和韧性方面找到了一线希望，所有这些都为疫苗和疗法的开发和交付带来了前所未有的速度。第七届加速生物制药开发国际会议（AccBio 2021）汇集了行业领袖，分享过去一年的经验，并讨论如何将大流行期间的经验教训应用于生物制药开发的未来。演讲者强调了将源自非克隆细胞池的生物疗法引入临床、开发模块化或平台技术以及承担新风险等例子。这些使药物加速进入临床和上市的策略，以及维持强大的供应链的策略，很可能会被纳入未来的计划中，以确保生物制造的弹性，并使药物更快地惠及患者，超过大流行前的速度。
